This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Techne (TECH) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 19.33% and 7.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QGEN vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
QGEN vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 19.12% and 9.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Techne (TECH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 25.44% and 9.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Completes Final Patient Treatment in Dry Eye Study
by Zacks Equity Research
Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
by Zacks Equity Research
Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.
Alexion's Ultomiris Gets Approval in Japan for Rare Disease
by Zacks Equity Research
Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA
by Zacks Equity Research
The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.
Alexion's New Formulation of Ultomiris Gets CHMP Backing
by Zacks Equity Research
Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab
by Zacks Equity Research
Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.
Immunomedics Releases Trodelvy Data From Cancer Studies
by Zacks Equity Research
Immunomedics (IMMU) releases data from different cancer studies on its lead drug, Trodelvy.
ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.
Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers
by Zacks Equity Research
Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.
Apellis Submits Pegcetacoplan Applications to FDA and EMA
by Zacks Equity Research
Apellis (APLS) submits an NDA to the FDA and an MAA to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.
Novartis' Eye Drug's Safety Label Update Approved by EMA
by Zacks Equity Research
Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.
Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall
by Zacks Equity Research
Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.
Immunomedics to be Acquired by Gilead for About 21 Billion
by Zacks Equity Research
Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.
Bayer Collaborates With Recursion for Fibrotic Diseases
by Zacks Equity Research
Bayer (BAYRY) inks deal with Recursion Pharmaceuticals for the treatment of fibrotic diseases.
Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.
Gilead Submits sBLA to FDA for CAR-T in Non-Hodgkin Lymphomas
by Zacks Equity Research
Gilead submits a supplemental Biologics License Application to the FDA for Yescarta for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Horizon Therapeutics' Stock Rises YTD on Approvals & Buyouts
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. It is making efforts to expand the label for its marketed drugs.